Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion

Hepatology

Volumn 48, Issue 3, 2008, Pages 759-769

  Evans, Alexander ^a   Riva, Antonio ^a   Cooksley, Helen ^a   Phillips, Sandra ^a   Puranik, Smrithi ^a   Nathwani, Amit ^b   Brett, Sara ^c   Chokshi, Shilpa ^a   Naoumov, Nikolai V ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD3 ANTIGEN; CD8 ANTIGEN; CELL PROTEIN; GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 10; LAMIVUDINE; MESSENGER RNA; PROGRAMMED DEATH 1 PROTEIN; TELBIVUDINE; UNCLASSIFIED DRUG;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; IMMUNOTHERAPY; LIVER BIOPSY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION; VIREMIA; VIRUS INHIBITION; VIRUS REPLICATION;

ADULT; ALANINE TRANSAMINASE; ANTIGENS, CD; ANTIVIRAL AGENTS; APOPTOSIS REGULATORY PROTEINS; BIOPSY; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; LAMIVUDINE; LIVER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NUCLEOSIDES; PYRIMIDINONES; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 51349132036     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22419     Document Type: Article

References (32)

1. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-229.
2. Ferrari C, Peoria A, Bertoletti A, Valli A, Antoni AD, Giuberti T, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145:3442-3449.
3. Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, et al. Longitudinal analysis of CD8+T-cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: Implications for immunotherapy. J Virol 2004;78:5707-5719.
4. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, et al. The cytotoxic T-lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181:1047-1058.
5. +T-lymphocytes after infection with hepatitis C virus. J Virol 2001;75:5550-5558.
6. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8+ T-cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.
7. Fung-Leung WP, Kundig TM, Zinkernagel RM, Mak TW. Immune response against lymphocytic choriomeningitis virus infection in mice without CD8 expression. J Exp Med 1991;174:1425-1429.
8. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499-1512.
9. Gruner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schrauc WW, et al. Association of hepatitis C virus-specific CD8+ T-cells with viral clearance in acute hepatitis C. J Infect Dis 2000;181:1528-1536.
10. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et Restoring function in exhausted CD8 T-cells during chronic viral infection. Nature 2006;439:682-687.
11. + T-cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-1202.
12. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T-cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350-354.
13. Colle JH, Moreau JL, Fontanet A, Lambotte O, Joussemet M, Delfraissy JF, et al. CD127 expression and regulation are altered in the memory CD8+T-cells of HIV-infected pacients - reversal by highly active anti-retroviral therapy (HAART). Clin Exp Immunol 2006;143:398-403.
14. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006;80:11398-11403.
15. +T-cells identifies functionally and phenotypically defined memory T-cells during acute resolving hepatitis B virus infection. J Virol 2006;80:3532-3540.
16. Milich DR, Liang TJ. Exploring the biological basis of hepatitis B e-antigen in hepatitis B virus infection. HEPATOLOGY 2003;38:1075-1086.
17. Chen M, Sallberg M, Hughes J, Jones J, Guidotti LG, Chisari FV, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005;79:3016-3027.
18. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e-antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A 1990;87:6599-6603.
19. Ishak K, Baptista A, Bianchi L, Callea F, De GJ, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
20. Garson JA, Grant PR, Ayliffe U, Ferns RB, Tedder RS. Real-time PCR quantitation of hepatitis B virus DNA using automated sample preparation and routine cytomegalovirus internal control. J Virol Methods 2005; 126:207-213.
21. Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, et al. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B antiviral and immunological activity. HEPATOLOGY 2005;42:1028-1036.
22. Rehermann B, Naoumov NV. Immunological rechniques in viral hepatitis. J Hepatol 2007;46:508-520.
23. Rigopoulou EL Abbott WG, Williams R, Naoumov NV. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Res 2007;75:36-42.
24. Lau G, Cooksley H, Ribeiro RM, Powers KA, Shudo E, Bowden S, et al. Impact of early viral kinetics on T-cell reactivity during anti-viral therapy in chronic hepatitis B. Antiviral Ther 2007;12:705-718.
25. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215-4225.
26. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, et al. Dysfunction and functional restoration ofHCV-specific CD8 responses in chronic hepatitis C virus infection. HEPATOLOGY 2007;45:588-601.
27. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco, N, Rosen HR. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+T-cells associated with reversible immune dysfunction. J Virol 2007;81:9249-9258.
28. Martinic MM, von Herrath MG. Novel strategies to eliminate persistent viral infections. Trends Immunol 2008;29:116-124.
29. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. HEPATOLOGY 2002;36:186-194.
30. Cooksley H, Chokshi S, Maayan Y, Wedemeyer H, Andreone P, Gilson R, et al. Hepatitis B e-antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+T-cell reactivity. Antimicrob Agents Chemother 2008;52:312-320.
31. Marinos G, Naoumov NV, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. HEPATOLOGY 1996;24:991-995.
32. Bertoletti A, Naoumov NV. Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol 2003;39:115-124.